AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 112 min read$CGEM

Cullinan Therapeutics To Present Phase 3 REZILIENT3 Data At IASLC 2026 On Sunday

Cullinan Therapeutics (CGEM) announced positive interim results from its Phase 3 REZILIENT3 trial of Zipalertinib for EGFR exon 20 insertion mutation-positive NSCLC. The trial met its primary endpoint of progression-free survival. Data will be presented at IASLC 2026. CGEM had $356.0M in cash as of Q2 2026. The stock closed at $21.00, down 1.45%.

Original reporting
rttnews.com
Published Sep 11, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CGEM
Bullish
high confidence
Mentioned
$CGEM
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CGEMBullishHigh
01

Why it matters

The interim REZILIENT3 results represent the first public confirmation of efficacy for Zipalertinib in EGFR exon‑20 NSCLC, a rare mutation with high unmet need.

02

Market read

Positive Phase 3 data are a strong catalyst for CGEM and may influence valuation of similar oncology assets.

03

What to watch

Potential competition from other EGFR exon‑20 agents and reimbursement uncertainties.

Relevance 8/10Novelty 9/10Timing: presentation Sep 13, 2026 (pre‑market)

Background

Cullinan Therapeutics (CGEM) is a clinical‑stage biopharma focused on T‑cell engagers and targeted cancer therapies.

Company-level read

Ticker impact

$CGEMBullishHigh confidence
Context

Interim Phase 3 REZILIENT3 data met primary endpoint; results presented Sep 13, 2026.

Expected impact

Potential upside of 10‑15% in the days following the presentation.

Evidence & confidence

Phase 3 success is a material catalyst for a clinical‑stage biotech.

Market effects

Sector

Boosts confidence in EGFR exon‑20 inhibitor space and may lift peer biotech stocks.

Regional

Positive for US biotech sector; limited direct regional effect.

Global

Highlights progress in targeted lung‑cancer therapies worldwide.

Counterpoint

What could challenge this read

If data later show limited durability, the rally could be short‑lived.

Key entities

  • Company
    Cullinan Therapeutics Inc.

    Clinical‑stage biotech developing Zipalertinib.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 13
$CGEMMedAI 8/10

Zipalertinib plus chemo shows survival benefit in lung cancer trial

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib plus chemotherapy in lung cancer. The combination improved progression-free survival by 6.0 months (14.5 vs. 8.5 months) with a hazard ratio of 0.50. The trial enrolled 279 patients, with objective response rates of 65.0% for the combination vs. 40.3% for chemotherapy alone. Zipalertinib is not yet approved.

investing.com2 min
SEP 13
$CGEMHighAI 8/10

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced positive Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC. The combination showed a 6.0-month median PFS improvement (HR=0.50, P=0.00015) and higher response rates. Data were presented at WCLC 2026. The companies plan to discuss results with health authorities.

finance.yahoo.com3 min
AUG 22
$CGEMMedAI 8/10

Why Cullinan Therapeutics (CGEM) Is Up 6.6% After Zipalertinib’s Positive Phase 3 Lung Cancer Data And What's Next

Cullinan Therapeutics (CGEM) shares rose 6.6% after positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant progression-free survival benefits. This positions zipalertinib as a potential first-line treatment for a specific subset of non-small cell lung cancer patients, supporting planned U.S. regulatory filings. Cullinan Therapeutics has no revenue but holds a high-risk pipeline with potential in oncology and autoimmune diseases.

simplywall.st3 min
AUG 21
$CGEMMedAI 9/10

Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant improvement in progression-free survival for patients with EGFR exon 20 insertion mutations. The companies plan to submit full results for presentation at an upcoming medical conference and pursue U.S. regulatory approval. Zipalertinib would compete with Johnson & Johnson's amivantamab (Rybrevant) i

geneonline.com2 min
AUG 20
$CGEMMedAI 8/10

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

Taiho Oncology and Cullinan Therapeutics (CGEM) announced that Phase 3 REZILIENT3 trial data for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC will be presented at the 2026 IASLC World Conference. The trial met its primary endpoint of progression-free survival. Zipalertinib is an investigational EGFR inhibitor.

biospace.com2 min